Capecitabine Market Size & Share 2023 to 2032
Market Size by Indication (Breast, Colorectal, Gastric, Pancreatic), by Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode.
Report ID: GMI6855
|
Published Date: October 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Capecitabine Market Size
Capecitabine Market size was valued to be USD 408.2 million in 2022 and is expected to reach USD 652.9 million in 2032 with a CAGR of 4.9% from 2023 to 2032 driven by a number of important factors, such as capecitabine has demonstrated significant clinical effectiveness in treating different cancer types over the years. It is particularly valued for its role in adjuvant therapy (post-surgery) and as a component of combination regimens for metastatic disease and hence its proven efficacy drives its use in cancer treatment.
Capecitabine Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Furthermore, the increasing global population susceptible to various cancer types such as colorectal cancer, breast cancer, and gastric cancer, serves as a significant driver of the capecitabine industry expansion. According to the report published by World Cancer Research Fund International, 2020 saw an estimated 18.1 million cancer cases worldwide, with breast cancers emerging as the most prevalent, contributing 12.5% to the total number of new diagnoses that year.
Capecitabine is a chemical compound used as the active pharmaceutical ingredients in formulations, particularly in the manufacturing of medications for cancer treatment. As an API, capecitabine is synthesized and formulated as tablets to be administered orally as part of cancer treatment regimens.
COVID-19 Impact
The COVID-19 pandemic had a notable effect on the overall economy, with its most significant impact occurring in the early months of 2020. During this period, the closure of numerous API manufacturing facilities due to the pandemic led to various challenges for the API industry. Some of these challenges included reduced operational capacity due to labor shortages, disruptions in the supply chain, and difficulties in sourcing raw materials and packaging materials. However, as the COVID-19 crisis continued to unfold, especially in the latter half of 2020, there was a surge in demand for specific pharmaceuticals, driving increased demand for APIs used in the production. the market experienced significant growth due to the heightened demand for medications during the COVID-19 pandemic.
Capecitabine Market Driving Factors
The increasing incidence of cancer is among a significant driver influencing the industry gains. Cancer has emerged as a global health challenge, with a steadily increasing burden of new cancer cases reported each year. This surge in cancer incidences is driven by factors such as aging populations, lifestyle changes, environmental factors, and increased cancer screening and detection efforts. Further, the most straightforward impact of rising cancer incidence and prevalence is the larger pool of patients who require cancer treatment. With more individuals diagnosed with cancer, the demand for cancer drugs, including capecitabine, also increases. For instance, according to the American Cancer Society, Inc., around 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023, and approximately 609,820 cancer-related fatalities in the U.S. in 2023, which is about 1,670 deaths per day.
Capecitabine Restraint
The high manufacturing costs in the capecitabine market is a complex issue with several detailed factors contributing to this challenge. Capecitabine API originates using a multistep process. Each stage necessitates careful monitoring of reaction conditions as well as the use of specialized equipment, reagents, and solvents. Due to the requirement for experienced workers and expensive infrastructure, the complex nature of the synthesis process can push up production prices. In addition, to ensure its safety and efficacy in cancer therapy, capecitabine API must comply with stringent quality and purity criteria. Manufacturers must spend in quality control procedures, analytical testing, and regulatory compliance, all of which can raise manufacturing costs.
Capecitabine Market Analysis
Based on the indication, the capecitabine market is segmented into breast cancer, colorectal cancer, gastric cancer, pancreatic cancer and other indications. The breast cancer segment is expected to reach USD 265.8 million by end of 2032. This leading market share is owing to the rising prescriptions of capecitabine for the treatment of metastatic breast cancer due to its proven efficacy. Capecitabine is an approved prodrug used for the treatment of metastatic breast cancer. It can be used as a single-agent chemotherapy or in combination with other chemotherapy drugs, such as docetaxel, Lapatinib, Oxaliplatin, Bevacizumab, etc.
Based on the synthesis type, the capecitabine market is classified into chemical-based API, biological API, and highly potent API (HPAPI). The chemical-based API segment dominated the market with 58.1% revenue share in 2022 and is projected to expand at 4.7% CAGR from 2023-2032. There is a growing focus on sustainability in pharmaceutical manufacturing, including the production of chemical-based APIs. Companies are adopting green chemistry practices, reducing waste, and optimizing processes to minimize environmental impact. In addition, to meet the increasing demand for capecitabine and other cancer therapies, pharmaceutical companies are expanding their production capacities. This involves investing in new manufacturing facilities and equipment. Furthermore, innovations in chemical synthesis techniques are enhancing the efficiency and yield of capecitabine production.
Based on the mode, the global capecitabine market is fragmented into in-house manufacturing and contract manufacturing. The potential for progression in this sector is substantial, driven by the prominent trend of continuous process optimization. This trend focuses on enhancing efficiency, cutting down manufacturing expenses, and minimizing environmental footprints. To optimize capecitabine API production, manufacturers are applying efficient production techniques, automation, and enhanced process monitoring. Along with this, as demand for capecitabine and cancer medicines increases, pharmaceutical companies are increasing their in-house production capacity. This may entail building new facilities or improving current ones to meet rising production demands.
In 2022, the North American region capecitabine market anticipated to witness significant progression to reach USD 252.5 million by end of 2032. In North America, the market for Capecitabine API is characterized by a well-established network of pharmaceutical manufacturers, both domestic and international. These manufacturers adhere to rigorous regulatory standards set forth by authorities such as the U.S. Food and Drug Administration (FDA) and Health Canada to ensure product safety, quality, and efficacy. The stringent regulatory oversight is essential in maintaining the high standards required for pharmaceutical ingredients. Moreover, North America remains a global hub for cancer research, with leading academic institutions, research centers, and pharmaceutical companies conducting extensive studies.
Capecitabine Market Share
Major players operating in the capecitabine is as mentioned below:
Capecitabine Company Market Share Analysis
Industry share within this capecitabine market is influenced by various factors, including product quality, regulatory compliance, pricing strategies, and the ability to effectively manage demand fluctuations. Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd and Shilpa Medicare limited accounts for largest market share in the overall industry. Further, adherence to regulatory requirements, such as good manufacturing practices (GMP), is crucial for building and retaining customer trust.
Capecitabine Market Industry News:
The capecitabine market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Indication
By Synthesis Type
By Mode
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →